A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide

A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide

Abstract The standard‐of‐care for patients with acute promyelocytic leukemia (APL) relapsing after upfront arsenic trioxide (ATO) therapy is not defined. The present study was undertaken to evaluate the safety of addition of bortezomib to ATO in the treatment of relapsed APL based on our previously...

Full description

Bibliographic Details
Main Authors: Uday Kulkarni, Saravanan Ganesan, Ansu Abu Alex, Hamenth Palani, Sachin David, Nithya Balasundaram, Arvind Venkatraman, Mani Thenmozhi, Lakshmanan Jeyaseelan, Anu Korula, Anup Devasia, Aby Abraham, Nancy Beryl Janet, Poonkuzhali Balasubramanian, Biju George, Vikram Mathews
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Cancer Medicine
Subjects:
arsenic trioxide
PML mutations
proteasome inhibitor
relapsed acute promyelocytic leukemia
Online Access:https://doi.org/10.1002/cam4.2883

Internet

https://doi.org/10.1002/cam4.2883

Similar Items